This is a staging instance. Full-text downloads are disabled.
 

Publication:
The role of atherogenic lipoproteins in diabetes: Molecular aspects and clinical significance

Simple item page
dc.contributor.authorBanerjee, Yajnavalka
dc.contributor.authorVichithran, Suhina
dc.contributor.authorFaisal, Shemima
dc.contributor.authorRizzo, Manfredi
dc.date.accessioned2023-10-30T09:31:03Z
dc.date.available2023-10-30T09:31:03Z
dc.date.issued2023
dc.description.abstractAbstract: Dyslipidaemia plays a prominent role in the genesis of atherosclerotic plaque and the increased cardiovascular risk in diabetes. Macrophages readily take up atherogenic lipoproteins, transforming into foam cells and amplifying vascular damage in the presence of endothelial dysfunction. We discuss the importance of distinct lipoprotein subclasses in atherogenic diabetic dyslipidaemia as well as the effects of novel anti-diabetic agents on lipoprotein fractions and ultimately on cardiovascular risk prevention. In patients with diabetes, lipid abnormalities should be aggressively identified and treated in conjunction with therapeutical agents used to prevent cardiovascular disease. The use of drugs that improve diabetic dyslipidaemia plays a prominent role in conferring cardiovascular benefit in individuals with diabetes.en_US
dc.identifier.other204-2023.97
dc.identifier.urihttps://repository.mbru.ac.ae/handle/1/1359
dc.language.isoenen_US
dc.subjectAtherosclerosisen_US
dc.subjectSmall Dense Lipoproteinen_US
dc.subjectInnovative Therapiesen_US
dc.subjectManagementen_US
dc.titleThe role of atherogenic lipoproteins in diabetes: Molecular aspects and clinical significanceen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files

Collections

Faculty Publications (CoM)